Carregant...
Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines
Background: Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the Australian Government Therapeutic Goods Administration (TGA) amended the indication to restrict use in BPSD to patients with...
Guardat en:
| Publicat a: | Pharmacy (Basel) |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6789876/ https://ncbi.nlm.nih.gov/pubmed/31336574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmacy7030100 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|